Organogenesis Holdings (ORGO) Current Deferred Revenue (2025)
Organogenesis Holdings (ORGO) recorded quarterly Current Deferred Revenue of $3.9 million in Q4 2025, up 166.09% quarter-over-quarter from $1.5 million in Q3 2025.
Organogenesis Holdings (ORGO) Current Deferred Revenue (2025) Analysis & Trends
Organogenesis Holdings' Current Deferred Revenue history runs 1 years deep, the most recent figure standing at $3.9 million for Q4 2025.
- In Q4 2025, Current Deferred Revenue changed N/A year-over-year to $3.9 million; the TTM figure through Dec 2025 stood at $3.9 million (changed N/A YoY), while the FY2025 annual figure was $3.9 million, changed N/A from the prior year.
- Current Deferred Revenue was $3.9 million for Q4 2025 at Organogenesis Holdings, up from $1.5 million in the prior quarter.
- In the past five years, Current Deferred Revenue ranged from a high of $3.9 million in Q4 2025 to a low of $1.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.34 Bn | 34.60 Bn | 1.97 Bn |
| 2 | Zoetis | 33.27 Bn | 31.33 Bn | 1.62 Bn |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn |
| 4 | Aurora Cannabis | 17.11 Bn | 17.03 Bn | 33.43 Mn |
| 5 | Neurocrine Biosciences | 16.37 Bn | 15.05 Bn | 800.70 Mn |
| 6 | Elanco Animal Health | 11.78 Bn | 11.35 Bn | 785.00 Mn |
| 7 | Alkermes | 7.05 Bn | 6.54 Bn | -116.06 Mn |
| 8 | Lantheus Holdings | 6.49 Bn | 5.99 Bn | 230.92 Mn |
| 9 | Hims & Hers Health | 6.19 Bn | 5.44 Bn | 396.79 Mn |
| 10 | Organogenesis Holdings | 304.80 Mn | 212.70 Mn | 11.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 3.86 Mn |
| Sep 30, 2025 | 1.45 Mn |
| Jun 30, 2025 | 2.09 Mn |